🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 3 quarters analysed

Q1 2026

Confident Specific

Management repeatedly stated 'gradual and incremental progress' and provided specific numeric targets (e.g., ID sales 2.8%, adjusted EBITDA $1.11B). They were direct in answering questions about gross margin drivers and e-commerce profitability, offering detailed breakdowns and forward guidance.

Q3 2026

Confident Specific

Management uses terms like 'we delivered', 'bold decisions', 'disciplined execution' and provides specific figures (2.4% ID sales, 21% digital growth, $1.039bn EBITDA) to reinforce confidence. The tone is forward-looking with quantified strategic bets and improved sequential unit trends.

Q4 2026 latest

Confident Specific

Management repeatedly emphasized confidence in strategy, productivity, and long-term growth, citing specific metrics like digital penetration surpassing 10%, 16% digital growth, and a $2B three-year productivity program. They directly addressed pharmacy headwinds and provided detailed guidance with explicit ranges for identical sales and EBITDA.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is slightly stronger after this call. Management demonstrated tangible progress in digital (16% growth, >10% penetration), loyalty (12% membership growth), and productivity (new $2B target), reinforcing their long-term growth narrative. The FY2026 guidance, while cautious on top-line due to IRA headwinds, shows a credible path to EBITDA growth via cost savings. However, near-term unit pressure and consumer uncertainty remain risks. Key items to watch next quarter: sequential identical sales improvement, gross margin trajectory, and early evidence of productivity savings flowing through. The increased dividend and share repurchase authorization signal confidence in cash flow generation.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 3 quarters Full tone analysis in Intelligence →

📊 MIXED Albertsons Q4 Adj. EBITDA $903M, raised dividend 13%, $2B buyback

Revenue & Profitability

Q4 identical-store sales increased 0.7% (net of 145 bps pharmacy headwinds). Full-year identical sales increased 2%. Q4 Adjusted EBITDA was $903 million (including $68 million from 53rd week). Full-year Adjusted EBITDA was $3.9 billion. Q4 Adjusted EPS was $0.48. Gross margin (ex-fuel and LIFO) was 27.2%, down 25 bps year-over-year. The company returned $1.8 billion to shareholders in fiscal 2025, including nearly $1.5 billion in share repurchases.

Outlook

Management noted industry units remain pressured, particularly in lower-income cohorts, and expects this pressure to persist in the first half of 2026. They expect sequential improvement in sales throughout the year, with positive volumes in the back half. Food inflation is expected to run around 2%. The outlook assumes the Middle East conflict ends in a reasonable period of time.

Growth Drivers

Digital sales grew 16% in Q4, with 90% from first-party. Loyalty membership grew 12% to more than 51 million. Own brands penetration is a top priority for 2026. The retail media business gained momentum with personalized ad pilots. Pharmacy script count continues to grow despite IRA headwinds.

Balance Sheet & CapEx

Fiscal 2025 capital expenditures were $1.84 billion, used to modernize store fleet (94 remodels, 9 new stores) and advance AI/digital/technology. Fiscal 2026 capital expenditures are expected to be $2.0-$2.2 billion, with new stores up about 50% from 2025 and significantly more remodels. The company launched a $2 billion three-year productivity program supported by AI big bets.

Margins

Gross margin in Q4 declined 25 bps year-over-year due to digital mix shift, offset by productivity. SG&A improved 2 bps year-over-year. For fiscal 2026, management expects gross margin flat to slightly better, with productivity offsetting price investments. Adjusted EBITDA growth at the top end of guidance is approximately 2.5% excluding the 53rd week. The company has a $2 billion three-year productivity program.

Key Risks

Risks mentioned include pharmacy headwinds from the Inflation Reduction Act (IRA) and moderation in GLP-1 growth due to tighter payer criteria. Egg deflation is a headwind in Q1 2026. Lower-income consumer pressure persists. Fuel costs could be impacted by the Middle East conflict. The company recorded a $774 million opioid settlement payable over nine years.

Generated by AI · Q4 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (4 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (4)

Q1 2027 Q1 2027 2026-07-23

Identical sales declined 0.8% year-over-year, with digital and pharmacy growth offset by core business pressures. The company launched the ACI Edge model to drive efficiency and expects $200 million in annual benefits by 2027, while updating guidance to reflect a challenging demand environment.

Q4 2026 Q4 2026 2026-04-14

Q4 and FY25 results exceeded expectations despite pharmacy headwinds, with strong digital and loyalty growth, disciplined capital allocation, and a raised productivity target. FY26 guidance anticipates modest sales growth, margin resilience, and continued investment in technology and stores.

Q3 2026 Q3 2026 2026-01-07

Q3 2025 delivered 2.4% identical sales growth and 21% digital sales growth, with strong pharmacy and digital performance. Guidance for fiscal 2025 was narrowed, reflecting pharmacy headwinds, but productivity and AI initiatives are driving margin improvement and long-term growth.

Q1 2026 Q1 2026 2025-07-15

Identical sales grew 2.8% year-over-year, led by pharmacy and digital, while adjusted EBITDA and EPS declined. FY2025 guidance was raised for sales growth, with continued investments in value, technology, and productivity expected to drive sequential improvement in grocery units and long-term growth.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.